These particular characteristics prompted the World Health Organization (WHO) in 2021 to refer mutant IDH GBM as grade 4 mutated IDH astrocytoma, to distinguish more clearly between this entity and wild-type IDH GBM [37]. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).